News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Vanda Pharmaceuticals secures global rights to develop and market Imsidolimab, an IL-36R antagonist, through agreement with Anaptys
Tuesday, February 04, 2025Vanda Pharmaceuticals and AnaptysBio have signed an exclusive global agreement for the development and commercialisation of imsidolimab an ILR antagonist monoclonal antibody The treatment has completed two Phase trials GEMINI and GEMINI assessing it...
TriLink BioTechnologies® collaborates with Avantor® to enhance nucleic acid solutions in Europe.
Monday, February 03, 2025TriLink BioTechnologies TriLink a Maravai LifeSciences company has formed a partnership with Avantor Inc to expand the availability of its nucleic acid products across Europe the Middle East and Africa EMEA This collaboration
Bristol Myers Squibb Receives Favourable CHMP Opinion for Opdivo and Yervoy as First-Line Treatment for Advanced Liver Cancer in Adults
Saturday, February 01, 2025Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA has recommended approval of Opdivo nivolumab plus Yervoy ipilimumab as a firstline treatment for adult patients with...
Axsome Therapeutics Receives FDA Approval for SYMBRAVO® to Treat Acute Migraine in Adults
Friday, January 31, 2025Axsome Therapeutics Inca biopharmaceutical company focused on central nervous system CNS disorders has received approval from the US Food and Drug Administration FDA for SYMBRAVO meloxicam and rizatriptan The treatment is intended for acute migraine...
Chugai and GSK Partner on Anti-Dengue Virus Antibody AID351
Friday, January 31, 2025Chugai Pharmaceutical Co Ltdhas entered into a collaboration agreement with GSKs Global Health Unit GSK GH to advance the development of an antidengue virus antibody Under this agreement GSK GH will assess potential funding and carry out activities t...
Siolta Therapeutics and Cowellnex Enter Joint Research Agreement
Thursday, January 30, 2025Siolta Therapeutics a leader in the development of live biotherapeutic products LBPs and Cowellnex Co Ltd a Kirin and Kyowa Kirin joint investment have signed a preclinical joint research agreement to develop an LBP aimed at the prevention of necroti...
Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe
Thursday, January 30, 2025Greenwich LifeSciences Inc a clinicalstage biopharmaceutical company focused on its Phase III clinical trial FLAMINGO which is evaluating GLSI an immunotherapy to prevent breast cancer recurrences today provided the following update on the expansion...
Akoya Biosciences Selects Argonaut Manufacturing Services as IVD Manufacturing Partner
Wednesday, January 29, 2025Argonaut Manufacturing Services a leading contract development and manufacturing organization serving the biopharma and life sciences industries and Akoya Biosciences Inc The Spatial Biology Company announced today that Argonaut will act as the manuf...
Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs
Wednesday, January 29, 2025Humacyte Inc a commercialstage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale and Pluristyx Inc today announced an expanded partnership Pluristyx makes and sells PluriBank iPSC lines a...
Apellis Gains Approval for SYFOVRE® (pegcetacoplan) in Australia to Treat Geographic Atrophy (GA)
Tuesday, January 28, 2025Apellis Pharmaceuticals Inchas announced that the Therapeutic Goods Administration TGA in Australia has approved SYFOVRE pegcetacoplan for the treatment of geographic atrophy GA secondary to agerelated macular degeneration AMD
